Azeliragon

Research use only, not for human use.

An orally bioavailable small molecule inhibitor of RAGE.

An orally bioavailable small molecule inhibitor of RAGE; inhibits sRAGE from binding to RAGE ligands, S100b, amphoterin and carboxymethyl-lysine; has been shown to inhibit the binding of sRAGE to Aβ1-42 in a fluorescent polarization assay; reduces accumulation in the spleen of Aβ peptides and the expression of IL-6 and macrophage colony stimulating factor, reduces both inflammatory markers (TNF-α, TGF-β and IL-1) and CNS amyloid deposition.Alzheimer's Disease Phase 3 Clinical

TTP-488;PF-04494700

Others

Other Targets

RAGE

Neurological Disease

Alzheimer Disease

603148-36-3

532.12

C32H38ClN3O2

>98% (HPLC)

10 mM in DMSO

CCCCC1=NC(=CN1C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OCCCN(CC)CC

1-Propanamine, 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl]phenoxy]-N,N-diethyl-

(-20℃)

With Ice Pack

≥ 2 years